Program
Docetaxel
Also written as “docetaxel”, “Taxotere” and “HB1801”.
Its studies are mostly in Breast Neoplasms · Carcinoma, Non-Small-Cell Lung · Prostatic Neoplasms · Stomach Neoplasms · Lung Neoplasms, led by 27 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofi | 540 open or running | phase 4since Jan 18, 2006 | Nov 1, 1999 | none ahead |
| Hoffmann-La Roche | 220 open or running | phase 4since Aug 5, 2005 | Feb 12, 2004 | none ahead |
| CSPC Pharmaceutical Group | 1511 open or running | phase 3since Apr 20, 2023 | Mar 10, 2021 | Dec 16, 2026phase 3 · NCT06747338 |
| Eli Lilly | 81 open or running | phase 3since Nov 1, 2004 | Nov 1, 2004 | May 2027phase 2 · NCT05999994 |
| Pfizer | 70 open or running | phase 2since Jan 4, 2002 | Jan 4, 2002 | none ahead |
| GlaxoSmithKline | 60 open or running | phase 2since Jul 17, 2003 | Jul 17, 2003 | none ahead |
| Amgen | 40 open or running | phase 2since Jul 5, 2000 | Jul 5, 2000 | none ahead |
| Merck | 30 open or running | phase 2since Oct 4, 2007 | Oct 4, 2007 | none ahead |
| novacea | 30 open or running | phase 3since Aug 9, 2002 | Aug 9, 2002 | none ahead |
| Novartis | 20 open or running | phase 3since Jun 29, 2004 | Jun 29, 2004 | none ahead |
| Samyang Biopharmaceuticals | 20 open or running | phase 1since Mar 21, 2011 | Mar 21, 2011 | none ahead |
| academy-military-medical-science-china | 10 open or running | phase 2since Jul 14, 2008 | Jul 14, 2008 | none ahead |
| Chong Kun Dang Pharmaceutical | 10 open or running | phase 1since Nov 23, 2009 | Nov 23, 2009 | none ahead |
| healthcare-global-enterprise-ltd | 10 open or running | phase 2since Sep 29, 2016 | Sep 29, 2016 | none ahead |
| hope-cancer-institute-inc | 10 open or running | phase 2since Nov 1, 1999 | Nov 1, 1999 | none ahead |
| Ionis Pharmaceuticals | 10 open or running | phase 2since Nov 2, 2010 | Nov 2, 2010 | none ahead |
| lidds-ab | 10 open or running | phase 1since Mar 18, 2021 | Mar 18, 2021 | none ahead |
| nanology-llc | 10 open or running | phase 1since Feb 5, 2020 | Feb 5, 2020 | none ahead |
| oshadi-drug-administration | 10 open or running | phase 2since May 7, 2014 | May 7, 2014 | none ahead |
| relmada-therapeutics-inc | 11 open or running | phase 2since Aug 8, 2024 | Aug 8, 2024 | Nov 2027phase 2 · NCT06663137 |
| Sarah Cannon Research Institute | 10 open or running | phase 2since Jun 27, 2007 | Jun 27, 2007 | none ahead |
| shanghai-miracogen-inc | 11 open or running | phase 3since Feb 22, 2023 | Feb 22, 2023 | none ahead |
| Simcere Pharmaceutical Group | 10 open or running | phase 1since May 25, 2020 | May 25, 2020 | none ahead |
| Sumitomo Pharma | 10 open or running | phase 1since Dec 7, 2020 | Dec 7, 2020 | none ahead |
| Swedish Orphan Biovitrum | 10 open or running | phase 3since Feb 5, 2003 | Feb 5, 2003 | none ahead |
| zhuhai-beihai-biotech-co-ltd | 11 open or running | phase 2since Dec 9, 2024 | Dec 9, 2024 | none ahead |
| zivena | 10 open or running | phase 2since May 11, 2004 | May 11, 2004 | none ahead |
Also a collaborator on its studies: Parexel, Jazz Pharmaceuticals Ireland, Baili-Bio (Chengdu) Pharmaceutical, Clovis Oncology, Astellas Pharma, Exelixis, Gilead Sciences, iTeos Belgium, Intas Pharmaceuticals, Lambda Therapeutic Research, Medigen Biotechnology, US Biotest, Quintiles, MDS Pharma Services, AstraZeneca and Regeneron Pharmaceuticals.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 46 studies since Oct 13, 2008.
- Feb 22, 2023shanghai-miracogen-inc’s first study: phase 3 study in Advanced or Metastatic Urothelium CancerNew to shanghai-miracogen-incshanghai-miracogen-inc · NCT05754853 · 290 planned · China
- Apr 20, 2023Phase 3 study in Breast NeoplasmsCSPC Pharmaceutical Group · NCT05838066 · 880 planned · China
- May 8, 2023Phase 2 study in Carcinoma, Non-Small-Cell LungCSPC Pharmaceutical Group · NCT05863325 · 80 planned · China
- Aug 14, 2023Phase 2 study in NeoplasmsEli Lilly · NCT05999994 · 105 planned · United States, Australia, Belgium and more
- Feb 28, 2024Phase 3 study in Stomach NeoplasmsCSPC Pharmaceutical Group · NCT06296706 · 630 planned · China
- Mar 13, 2024Phase 3 study in Squamous Cell Non-small Cell Lung CancerCSPC Pharmaceutical Group · NCT06319313 · 534 planned
- Jun 24, 2024Phase 3 study in Advanced Pancreatic CancerCSPC Pharmaceutical Group · NCT06492941 · 142 planned
- Aug 8, 2024relmada-therapeutics-inc’s first study: phase 2 study in Non-Muscle Invasive Bladder NeoplasmsNew to relmada-therapeutics-increlmada-therapeutics-inc · NCT06663137 · 70 planned · Israel
- Dec 9, 2024zhuhai-beihai-biotech-co-ltd’s first study: phase 2 study in Urinary Bladder NeoplasmsNew to zhuhai-beihai-biotech-co-ltdzhuhai-beihai-biotech-co-ltd · NCT06732531 · 48 planned · China
- Dec 13, 2024Phase 3 study in Early or Locally Advanced HER2-positive Breast CancerCSPC Pharmaceutical Group · NCT06747338 · 520 enrolled · China
- Jul 15, 2025Phase 2 study in Advanced Breast CancerCSPC Pharmaceutical Group · NCT07083505 · 60 planned
- Aug 7, 2025Phase 2 study in HER2-positive Breast CancerCSPC Pharmaceutical Group · NCT07116824 · 80 planned
- Feb 12, 2026Phase 3 study in Resectable HER2-positive Breast CancerCSPC Pharmaceutical Group · NCT07441460 · 1,800 planned · China
- Aug 28, 2026Phase 3 study in HER2-Negative Advanced Breast CancerCSPC Pharmaceutical Group · NCT07805135 · 430 planned
Ahead
- Dec 16, 2026Primary completion: phase 3 study in Early or Locally Advanced HER2-positive Breast CancerCSPC Pharmaceutical Group · NCT06747338
- May 2027Primary completion: phase 2 study in NeoplasmsEli Lilly · NCT05999994
- Nov 2027Primary completion: phase 2 study in Non-Muscle Invasive Bladder Neoplasmsrelmada-therapeutics-inc · NCT06663137
- Jun 1, 2028Primary completion: phase 3 study in HER2-Negative Advanced Breast CancerCSPC Pharmaceutical Group · NCT07805135
TargetBeta
“Tubulin inhibitor; Tubulin stabiliser”ChEMBL 37, by rule
Other programs on the same 15 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Paclitaxelrule | Hoffmann-La Roche | phase 4 | 202 |
| cabazitaxelrule | Sanofi | phase 4 | 21 |
| Vinblastinerule | Takeda | phase 4 | 4 |
| desoxyepothilone Brule | beijing-biostar-pharmaceuticals-co-ltd | phase 3 | 19 |
| plinabulinrule | beyondspring-pharmaceuticals-inc | phase 3 | 8 |
Studies
The newest 60 of 142 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07805135HER2-Negative Advanced Breast Cancer | 3 | Not yet recruiting | CSPC Pharmaceutical Group | Jun 1, 2028 | 430 |
| NCT07441460Resectable HER2-positive Breast Cancer · China | 3 | Recruiting | CSPC Pharmaceutical Group | Aug 7, 2034 | 1,800 |
| NCT07116824HER2-positive Breast Cancer | 2 | Not yet recruiting | CSPC Pharmaceutical Group | Jul 15, 2026 | 80 |
| NCT07083505Advanced Breast Cancer | 2 | Not yet recruiting | CSPC Pharmaceutical Group | Oct 11, 2026 | 60 |
| NCT06747338Early or Locally Advanced HER2-positive Breast Cancer · China | 3 | Active, not recruiting | CSPC Pharmaceutical Group | Dec 16, 2026 | 520 |
| NCT06732531Urinary Bladder Neoplasms · China | 2 | Recruiting | zhuhai-beihai-biotech-co-ltd | Dec 2025 | 48 |
| NCT06663137Non-Muscle Invasive Bladder Neoplasms · Israel | 2 | Recruiting | relmada-therapeutics-inc | Nov 2027 | 70 |
| NCT06492941Advanced Pancreatic Cancer | 3 | Not yet recruiting | CSPC Pharmaceutical Group | Apr 14, 2026 | 142 |
| NCT06319313Squamous Cell Non-small Cell Lung Cancer | 3 | Not yet recruiting | CSPC Pharmaceutical Group | Jul 1, 2026 | 534 |
| NCT06296706Stomach Neoplasms · China | 3 | Recruiting | CSPC Pharmaceutical Group | Jun 1, 2026 | 630 |
| NCT05999994Neoplasms · United States, Australia, Belgium and more | 2 | Recruiting | Eli Lilly | May 2027 | 105 |
| NCT05863325Carcinoma, Non-Small-Cell Lung · China | 2 | Recruiting | CSPC Pharmaceutical Group | Mar 2024 | 80 |
| NCT05838066Breast Neoplasms · China | 3 | Recruiting | CSPC Pharmaceutical Group | Jul 31, 2025 | 880 |
| NCT05754853Advanced or Metastatic Urothelium Cancer · China | 3 | Recruiting | shanghai-miracogen-inc | Oct 2025 | 290 |
| NCT05705635Gastric Adenocarcinoma · China | 2 | UNKNOWN | CSPC Pharmaceutical Group | May 2023 | 100 |
| NCT05616494Pancreatic Neoplasms · China | 2 | Recruiting | CSPC Pharmaceutical Group | Dec 31, 2024 | 53 |
| NCT05325229Platinum-resistant Recurrent Ovarian Cancer · China | 2 | UNKNOWN | CSPC Pharmaceutical Group | Dec 2024 | 94 |
| NCT05027204Squamous Cell Carcinoma of Head and Neck · China | 2 | UNKNOWN | CSPC Pharmaceutical Group | Oct 31, 2023 | 94 |
| NCT04810208Solid Tumor · Denmark, Lithuania, Sweden | 1 | Terminated | lidds-ab | Oct 7, 2021 | 6 |
| NCT04811118Advanced Solid Tumors · China | 1 | UNKNOWN | CSPC Pharmaceutical Group | Oct 31, 2022 | 27 |
| NCT04725188Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 2 | Completed | Merck | Jan 26, 2023 | 255 |
| NCT04666129Metastatic Castration-Resistant Prostate Cancer · United States | 1 | Completed | Sumitomo Pharma | May 28, 2024 | 48 |
| NCT04471428Carcinoma, Non-Small-Cell Lung · United States, Australia, Austria and more | 3 | Completed | Hoffmann-La Roche | Sep 28, 2022 | 366 |
| NCT04413227NSCLC · China | 1 | UNKNOWN | Simcere Pharmaceutical Group | May 31, 2021 | 30 |
| NCT04404140Prostatic Neoplasms, Castration-Resistant · France, Italy, Spain and more | 1 | Terminated | Hoffmann-La Roche | Oct 14, 2022 | 6 |
| NCT04260360Carcinoma, Renal Cell | 1 | Withdrawn | nanology-llc | Jun 2022 | 0 |
| NCT03739710Neoplasms · United States, Canada, France and more | 2 | Completed | GlaxoSmithKline | May 2, 2024 | 175 |
| NCT03337698Carcinoma, Non-Small-Cell Lung · United States, Australia, France and more | 2 | Terminated | Hoffmann-La Roche | Oct 14, 2025 | 314 |
| NCT02985255Tongue Neoplasms · India | 2 | UNKNOWN | healthcare-global-enterprise-ltd | Jun 2017 | 30 |
| NCT02831491Carcinoma, Non-Small-Cell Lung | 2 | Withdrawn | Eli Lilly | Jul 2017 | 0 |
| NCT02748213Breast Neoplasms · Australia, Brazil, Canada and more | 2 | Completed | Hoffmann-La Roche | Mar 2006 | 225 |
| NCT02605915Breast Neoplasms · United States | 1 | Completed | Hoffmann-La Roche | Nov 13, 2019 | 98 |
| NCT02445586Breast Neoplasms · India | 4 | Completed | Hoffmann-La Roche | Sep 26, 2018 | 52 |
| NCT02419742Breast Neoplasms · India | 4 | Completed | Hoffmann-La Roche | Jun 24, 2021 | 110 |
| NCT02402712Breast Neoplasms · Belgium, Bulgaria, Canada and more | 3 | Completed | Hoffmann-La Roche | Feb 22, 2019 | 418 |
| NCT02274610Solid Tumor | 1 | Completed | Samyang Biopharmaceuticals | Nov 2015 | 18 |
| NCT02134990Carcinoma, Non-Small-Cell Lung · Israel | 2 | UNKNOWN | oshadi-drug-administration | Jan 2019 | 20 |
| NCT02005549Breast Neoplasms · Austria | 2 | Completed | Hoffmann-La Roche | Apr 2008 | 18 |
| NCT01938456Carcinoma, Non-Small-Cell Lung | 1 | Withdrawn | GlaxoSmithKline | Jul 2014 | 0 |
| NCT01862081Breast Neoplasms · United States, Belgium, Canada and more | 1 | Completed | Hoffmann-La Roche | Jun 9, 2017 | 80 |
| NCT01718353Prostate Cancer Metastatic · United States, Canada | 2 | Completed | Sanofi | Aug 2015 | 63 |
| NCT01515748Stomach Neoplasms · Korea, Republic of | 3 | Completed | Sanofi | Jan 21, 2019 | 530 |
| NCT01336582Solid Tumor · Korea, Republic of | 1 | Completed | Samyang Biopharmaceuticals | Apr 2012 | 42 |
| NCT01266512Lung Neoplasms · Hong Kong | 2 | Completed | Sanofi | Mar 2014 | 34 |
| NCT01234025Castrate-Resistant Prostate Cancer · United States, Hungary, Poland and more | 2 | Completed | Ionis Pharmaceuticals | May 2013 | 113 |
| NCT01220128Breast Neoplasms · United States, Belgium, France and more | 2 | Terminated | GlaxoSmithKline | Nov 14, 2014 | 66 |
| NCT01148615Neoplasms · China | 1 | Completed | Sanofi | Sep 2011 | 20 |
| NCT01038661Lung Neoplasms · China | 3 | Completed | Sanofi | Aug 2012 | 375 |
| NCT01019941Advanced Solid Cancers · Korea, Republic of | 1 | Completed | Chong Kun Dang Pharmaceutical | Aug 2010 | 44 |
| NCT00964704Breast Neoplasms | 2 | Withdrawn | Hoffmann-La Roche | Aug 2013 | 0 |
| NCT00934856Breast Neoplasms · United States, France, Spain and more | 2 | Completed | Hoffmann-La Roche | Oct 2013 | 98 |
| NCT00927589Solid Cancers · United States | 1 | Completed | Hoffmann-La Roche | Feb 2013 | 59 |
| NCT00916097Head and Neck Neoplasms · Algeria, Morocco, Tunisia | 2 | Completed | Sanofi | Nov 2005 | 66 |
| NCT00845910Breast Neoplasms · Taiwan | 2 | Terminated | Hoffmann-La Roche | May 2011 | 22 |
| NCT00819728Carcinoma, Non-Small-Cell Lung · United States | 2 | Completed | Sanofi | 35 | |
| NCT00816543Stomach Neoplasms · Korea, Republic of | 2 | Completed | Sanofi | May 2012 | 41 |
| NCT00811447Stomach Neoplasms · China | 3 | Completed | Sanofi | Jun 2012 | 243 |
| NCT00774241Breast Neoplasms | 4 | Withdrawn | Hoffmann-La Roche | Nov 2013 | 0 |
| NCT00773695Breast Neoplasms · Norway | 2 | Completed | Hoffmann-La Roche | Nov 9, 2022 | 150 |
| NCT00826852Lung Neoplasms · Turkey | 2 | Completed | Sanofi | Jul 2009 | 49 |
How it is read
Names in the registry
- “Docetaxel”, 93 entries
- “docetaxel”, 37 entries
- “Taxotere”, 9 entries
- “HB1801”, 8 entries
- “Docetaxel for injection (Albumin-bound)”, 4 entries
Codes read as this program: CKD810.
Conditions, from the studies’ own filings
- Breast Neoplasms, 54 studies
- Carcinoma, Non-Small-Cell Lung, 48 studies
- Prostatic Neoplasms, 21 studies
- Stomach Neoplasms, 9 studies
- Lung Neoplasms, 7 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.